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Abstract
Background: Despite appropriate medical therapy, many horses with equine recurrent uveitis continue to suffer
from recurrent bouts of inflammation. Surgical intervention via the pars plana vitrectomy or suprachoroidal
cyclosporine implant placement may control and/or prevent recurrences, however, these procedures may be
contraindicated, unavailable, or declined by an owner. Thus, an effective adjunctive treatment option may
help to improve the clinical outcomes in those situations. There are several anecdotal reports on the use
of intravitreal gentamicin injections, but to date, no data evaluating the complication rate and/or treatment
effect following this treatment have been published. Thus, the aim of this prospective study was to describe
the intravitreal gentamicin injection technique, describe the associated peri-injection (within 24 h) and post-
injection (30 to 780 days) complications, and to report the effects of the injection on the clinical signs of
uveitis. Additionally, evaluation of the systemic and ocular Leptospira-status, and its effect on the treatment
outcome was performed. A total of 86 horses of various ages, breeds, and gender presenting with recurrent
or persistent uveitis were treated via intravitreal injection of 4 mg of undiluted gentamicin (0.04 ml, Genta 100,
100 mg/ml in 35 horses) or preservative-free gentamicin (0.05 ml, 80 mg/ml in 52 horses) under sedation and
local anesthesia. All 86 horses were observed for immediate peri-injection and post-injection complications.
Response to therapy was evaluated in 59 of the 86 horses (follow-up: 30 to 780 days).
Results: Peri-injection complications consisted of subconjunctival (26/86; 30.2%) or intracameral hemorrhage
(4/86; 4.7%); both of which completely resolved within 5 days. Post-injection complications consisted of
cataract formation/maturation (5/59 horses, 8.5%) and diffuse retinal degeneration (3/59 eyes 5.1%). The
majority of horses 52/59 (88.1%) with a minimum follow-up period of 30 days were controlled (absence
of recurrent or persistent inflammation) at their last recheck examination. Recurrent inflammation was
documented in 5/59 (8.5%) horses and persistent inflammation was diagnosed in 2/59 (3.4%) horses.
Conclusions: Intravitreal injection of low-dose gentamicin shows promise at controlling different types and
stages of uveitis. The ability of intravitreal injections of low-dose gentamicin (4 mg) to control persistent
and recurrent inflammation warrants further investigation.
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Background
Equine recurrent uveitis (ERU) is widely recognized as
an immune-mediated disease characterized either by
recurrent bouts of ocular inflammation separated by
variable periods of quiescence (lack of detectable ocular
signs associated with active inflammation) or low-grade,
persistent inflammation [1–3]. The cornerstone of treat-
ment for ERU consists of local immunosuppression or
immune-modulation in conjunction with systemic
anti-inflammatory treatment [4–7].
In addition to medical therapy, there are two widely
utilized surgical procedures, cyclosporine suprachoroidal
implants (CSI) and pars plana vitrectomy (PPV), that are
routinely performed to treat horses with ERU [8–14].
Implantation of a CSI has been proven to be an effective
means of controlling uveitis in horses responsive to prior
medical therapy [3, 8, 13, 15]. However, because their
legal importation into Europe is restricted to academic
institutions for specific use in ongoing research, the use
of CSI is severely limited on this continent. A more
commonly performed surgery in Europe (especially
Germany) is the PPV [9, 10, 14, 16]. Initially, PPV was
utilized to treat all forms of ERU, but recently published
data suggests that it is most effective in horses with con-
firmed leptospiral etiology [14].
Two recent studies demonstrated the relative inability
of medical therapy to adequately control and prevent
long-term complications and blindness in a large pro-
portion of horses evaluated, highlighting the importance
of additional treatment modalities [17, 18]. Intravitreal
injections with triamcinolone acetonide or rapamycin
have been successfully utilized in the management of re-
current uveitis in humans, as well as in small groups of
horses [19–23]. However, the rate of complications and
lack of long-term control of ERU, has limited their use
in equine ophthalmology. Gentamicin (0.2–0.4 mg/ml), a
bactericidal aminoglycoside antibiotic, has been rou-
tinely added to the PPV irrigation solution since the sur-
gery’s introduction in the early 1990s [9–11, 24]. This
led to speculation that low-dose intravitreal gentamicin
(4 mg) injections (IVGI) alone could serve as an alterna-
tive treatment for ERU, and initial results were presented
by Pinard, et al. in 2005 [25]. Despite widespread anec-
dotal use, there are no published studies evaluating the
efficacy of this treatment or establishing the risk of com-
plications following IVGI.
The purpose of this prospective study was to describe
the intravitreal gentamicin injection technique, to iden-
tify any peri-injection (within 24 h) and/or post-injection
(30 to 780 days follow-up) complications associated with
the IVGI and to evaluate the clinical outcome in horses
with ERU, following a single 4 mg IVGI. Additionally,
aqueous humor (AH) and serum (S) samples were evalu-
ated for the presence of leptospiral antibody titers (S and
AH) and leptospiral DNA (AH) and their effect on the
treatment outcome.
Results
Horses
A total of 86 horses with a mean follow-up period of
165.9 ± 190.3 days (range: 1 to 780 days) were included
in the present study. The mean age was 11.6 ± 5.5 years
(range: 2 to 28 years). Gender, breed and coat color dis-
tribution can be found in Table 1. Twenty-nine horses
were treated bilaterally, resulting in one eye being ran-
domly selected for evaluation.
Fifty-nine of the 86 eyes had a minimum follow-up
period of 30 days (range: 30 to 780 days) and comprised
the group undergoing statistical evaluation of
post-injection complications and clinical treatment out-
come. Fifty-two of 59 eyes (88.1%) were controlled (non--
recurrence/persistence, independent of complications)
after the IVGI, and despite the discontinuation of topical
and medical therapy. Overall, 5/59 eyes (8.5%) presented
with recurrent and 2/59 eyes (3.4%) presented with per-
sistent inflammation during follow-up examination. The
follow-up data and corresponding results of positive out-
come are listed in Table 2. Category distributions are listed
in Fig. 1, Tables 3 and 4.
Leptospira status
Aqueous humor was obtained from 79/86 (91.9%) eyes
and serum from 80/86 (93%) horses. Table 5 shows the
calculated c-values for each individual Leptospira serovar
and the combined results are documented in Table 6.
Leptospira PCR was performed on 79 eyes, 23 of which
were positive 23/79 (29.1%). Based on our inclusion
criteria and calculation of c-values for each eye 50/79
eyes (63.3%) were classified as Leptospira negative, 13/79
eyes (16.5%) were classified as Leptospira suspicious and
the remaining 16/79 eyes (20.3%) were classified as Lep-
tospira positive.
Peri-injection complications
Subconjunctival and intracameral hemorrhage (due to
the aqueous paracentesis) were seen in 26/86 (30.2%)
and 4/86 (4.7%) of the eyes, respectively, but were com-
pletely resolved within 5 days.
Post-injection complications
Fifty-nine of 86 eyes had a minimum follow-up period of
30 days (30–780 days) and were evaluated for the pres-
ence of post-injection complications. Cataract forma-
tion/maturation was observed in 5/59 (8.5%) eyes, and
retinal degeneration was seen in 3/59 eyes (5.1%). Four
of the five cataracts that developed post-injection were
identified in horses that received gentamicin with preser-
vatives. Cataract progression/maturation occurred within
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one week (1/5, 20%), within one year (3/5, 60%), and
later than one year post-IVGI (1/5, 20%). All eyes, that
developed mature cataracts, presented with cataracts of
different stages before IVGI (Fig. 2). Retinal degener-
ation, not associated with obvious visual deficits (as
assessed via menace response), was identified in 3/59
(5.1%) eyes (Fig. 3), and was consistently identified as a
horizontal, geographic area (between one and three disc
diameters in size) of diffuse tapetal hyperreflectivity
superior to the optic nerve head. This complication was
identified in a single eye at each of the following time
points: Within 30 days, between 30 and 60 days, and
between 90 and 122 days following IVGI, respectively.
None of these eyes showed signs of retinal degeneration
prior to IVGI.
Statistical evaluation of factors influencing treatment
outcomes and complication rates
Variables with a significant effect on treatment outcome
or on the development of long-term complications, are
presented in Table 7. A significant correlation was iden-
tified between the Appaloosa breed and recurrence of
inflammation (P < 0.001). In each of these horses, uveitis
remained controlled in the early stages of follow-up.
However, over time, aqueous flare was detectable in all
three eyes. Leopard-patterned horses were more likely to
develop recurrent inflammation than horses with other
coat colors (P = 0.049). None of the eyes, that developed
retinal degeneration, had detectable aqueous flare
pre-IVGI (P = 0.046). The presence of subconjunctival or
intracameral hemorrhage post-IVGI did not have a
significant influence on either the control of the uveitis,
or the development of long term-complications. Neither
the clinical diagnosis, nor the additional categories utilized
to subjectively grade equine uveitis in the present study
had any influence on the control of the uveitis or the de-
velopment of post-injection complications. The Leptospira
antibody status of the eye (positive, suspicious, or negative
C-value) and aqueous humor Leptospira PCR results did
not have a significant influence on the development of
long-term complications. There was a significant influence
on the development of persistent inflammation in one eye
with multiple positive C-values ≥4 (C-value of 8 for L.
pomona and C-Value of 4 for L. grippotyphosa)
(P = 0.015), multiple aqueous humor titers ≥1:400 (aqueous
humor titer for L. Pomona 1:800 and for L. grippoty-
phosa 1:1600) (P = 0.013) and one positive serum
titer ≥1:400 (serum titer for L. grippotyphosa 1:400)
(P = 0.047). Although not significant, 4/5 (80%)
mature cataracts developed following IVGI injection
with gentamicin containing preservatives (Genta100).
Discussion
Many horses with ERU require additional treatment mo-
dalities in addition to medical therapy. Both the PPV
and CSI placement are commonly performed in Europe
and the USA, respectively [8, 15, 16, 26]. Although CSI
placement can effectively suppress intraocular
Table 1 Gender, breed and coat color distribution of the horses
(n = 86) that had undergone IVGI between January 2013 – June
2016
Gender n = 86 Geldings 49 (57%)
Mares 31 (36%)
Stallions 6 (7%)
Breed n = 86 Warmblood 38 (44.2%)
Quarter Horse; Paint Horse 9 (10.5%)
Icelandic Horse 6 (7.0%)
Pony 6 (7.0%)
Heavy Warmblood 5 (5.8%)
Standardbred Trotter 5 (5.8%)
Haflinger 5 (5.8%)
Appaloosa 4 (4.7%)
Spanish 3 (3.5%)
Knabstrupper 3 (3.5%)
Thoroughbred 2 (2.3%)
Coat Color Distribution
n = 86
Bay 36 (41.9%)
Chestnut 16 (18.9%)
Gray 11 (12.8%)
Leopard-patterned 11 (12.8%)
Black 7 (8.1%)
Dun 5 (5.8%)
Table 2 Follow-up periods and clinical outcomes post-intravitreal gentamicin injections
Minimum follow-up period Controlled ERU
(no recurrent or
persistent inflammation,
independent of
complications)
Average follow-up
period (days)
Standard deviation
(± days)
Range (days)
30 days 59/86 (68.6%) eyes 52/59 eyes 88.1% 238 190 30–780
3month 43/86 (50.0%) eyes 36/43 eyes 83.7% 313 175 93–780
5month 34/86 (39.5%) eyes 27/34 eyes 79.4% 359 164 153–780
7month 24/86 (27.9%) eyes 20/24 83.3% 407 170 213–780
1 year 12/86 (14.0%) eyes 9/12 eyes 75% 541 137 365–780
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inflammation and prevent recurrent inflammatory bouts
for several years, they are not readily available in Europe
due to legal restrictions governing their importation.
Additionally, there are several instances where PPV (e.g.,
radial retinal detachments, late immature to mature cat-
aracts present) or CSI (e.g., uncontrollable inflammation
despite appropriate medical therapy) are contraindicated.
Thus, additional or alternative treatment options, such
as IVGI, may enable us to better control this highly de-
bilitating disease. attractive.
Aqueous paracentesis and IVGI can be performed dur-
ing the same sedation, using minimal regional and topical
anesthesia; thus, negating the need for general anesthesia.
Ultimately, only those horses not being controlled with
IVGI require additional surgical intervention. This has
dramatically reduced the number of horses requiring sur-
gical intervention to control ERU in our clinic population.
However, if an eye fails to be controlled with IVGI, the
Leptopsira status, previously obtained via aqueous para-
centesis, can then be used to choose the most appropriate
surgical intervention, e.g., a PPV or CSI.
Serum Leptospira antibodies are able to effectively
cross the blood-ocular barriers in the presence of
uveitis, therefore only local antibody production at
the site of the inflamed tissue is a true indicator for a
Leptospira-induced mechanism of action. Individual
aqueous humor or serum antibody titers are unreli-
able predictors of involvement [27]. In order to accur-
ately identify Leptospira’s role in the pathogenesis of
equine uveitis it is important to calculate the c-value
(i.e., the ratio between aqueous humor and serum
antibody titers) [14].
The main goals in treating ERU are the reduction of
ocular inflammation, the reduction or elimination of
pain or discomfort, and the preservation of vision [3,
17]. According to a recent study by Gerding and Gilger,
nearly half of the eyes affected with uveitis became blind,
regardless of the therapy implemented [17]. In a study
from Germany, evaluating the post-operative results fol-
lowing PPV for the treatment of ERU, 17/43 (39.5%) of
the eyes had improved vision, 14/43 (32.6%) of the eyes
demonstrated reduced vision, and 12/43 (27.9%) of the
eyes were blind following the surgery [12]. Long-term re-
sults following implantation of a CSI revealed that 119/
151 (78.8%) of the eyes remained visual [13]. Although the
results of the present study (Table 4) are not directly com-
parable with the previous reports, the vision status of the
eyes in this study remained unchanged following IVGI in
71.2% (42/59) eyes, were improved in 18.6% (11/59) eyes,
and deteriorated in 10.2% (6/59) eyes. Each eye that devel-
oped mature cataracts post-IVGI had some degree of im-
mature cataract maturation prior to IVGI (Fig. 2). Despite
Table 3 Characteristics of uveitis
acute/chronic n = 86 eyes acute
4 (4.7%)
chronic
25 (29.1%)
chronic-acute
57 (66.3%)
recurrent/persistent
n = 86 eyes
recurrent
36 (41.9%)
persistent
50 (58.1%)
presence of aqueous flare
n = 86 eyes
0 (no flare)
42 (48.8%)
1 (faint flare)
20 (23.3%)
2 (moderate flare)
13 (15.1%)
3 (severe flare)
3 (3.5%)
4 (blood or fibrin in
anterior chamber) 8 (9.3%)
Fig. 1 Distribution of clinical signs of uveitis
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this, the degree of cataract maturation prior to IVGI can-
not be reliably utilized to predict the likelihood of cataract
progression/maturation following IVGI. None of the
horses that developed post-IVGI retinal degeneration
demonstrated any subjective behavioral changes (e.g., head
carriage abnormalities (head tilt), spooky or erratic behav-
ior, hesitant to move or navigate obstacles in a known en-
vironment) suggesting that vision was compromised, nor
did they not show detectable clinical signs of vision loss
(menace response). However, we cannot conclude that vi-
sion was not compromised. Additional functional testing
methods, such as pre-IVGI and post-IVGI electroretinog-
raphy (ERG) would provide more objective and meaning-
ful results pertaining to retinal function, and should be
considered for future studies. Although none of the three
eyes that developed retinal degeneration had flare at the
time of IVGI, the clinical disease progression in each of
these horses differed significantly enough to prevent us
from drawing a reliable conclusion as to why this compli-
cation occurred. We cannot exclude that eyes presenting
with a mature cataract did not develop retinal degener-
ation. The risks of potential cataract maturation and retinal
degeneration cannot be ignored, and must be discussed in
detail with the owner when discussing treatment options.
There are many factors that will ultimately determine if an
IVGI is indicated, thus, it is important to provide an accur-
ate risk-benefit analysis for each individual horse. Further
investigation into the post-injection development of retinal
degeneration is warranted. Ongoing efforts include func-
tional testing via ERG and posterior segment evaluation via
optical coherence tomography (OCT). The fact that there
was a significant influence on the development of persistent
inflammation in one eye with multiple positive C-values ≥4
of different Leptospira titers, multiple aqueous humor Lep-
tospira titers ≥1:400 of different serovars and one positive
serum Leptospira titer ≥1:400 warrants further investiga-
tion, but caution must be taken when interpreting this data,
as only a single eye was affected. The complication rates
associated with IVGI (88.1% non-recurrence/non-persis-
tence rate, 8.5% cataract progression/maturation, and
5.1% retinal degeneration) are comparable to published
results following CSI placement (46% non-recurrence rate,
16% cataract progression/formation and 16% retinal
degeneration) and PPV (73.6–100% non-recurrence rate,
38.2–44.2% cataract progression/formation, and 9.3%
retinal degeneration) [9–14].
Presently, the mechanism of action of gentamicin on
the disease process in ERU and other types or stages of
equine uveitis remains enigmatic. Positive suppression of
inflammation, which can be observed as early as 24–48
h post-IVGI, was achieved in various types and stages of
equine uveitis despite the Leptospira status of the eye, in
the present study. Therefore, we speculate that rather
than having a direct bactericidal effect on putative
bacterial organisms, gentamicin instead influences or in-
terferes with the immune-mediated processes intrinsic
to ERU. Although purely speculative, the underlying
mechanism of action of gentamicin may block or sup-
press the activation of specific T-cell lines; cells that are
known to play a significant role in autoimmune uveitis
[28]. Further research into gentamicin’s mechanism of
action following intravitreal injection is necessary.
Limitations of the present study are the short
follow-up periods utilized for evaluation following IVGI.
Despite the short follow-up duration, a 30-day minimum
follow-up period was selected in order to capture the
immediate effects of IVGI and to ensure that all compli-
cations seen associated with this technique were
observed and recorded. Had we selected a longer mini-
mum follow-up period, 1/3 (33.3%) of the eyes that
Table 5 Single c-value results for individual Leptospira serovars
Result C-values for individual Leptospira (L.) serovars
sejroe
(n = 63)
saxkoebing
(n = 63)
canicola
(n = 63)
autum-nalis
(n = 79)
grippo-typhosa
(n = 79)
pomona
(n = 79)
australis
(n = 79)
ictero-haemorrhagiae/
copenhageni (n = 79)
bratislava
(n = 79)
Posititive (+) 0 0 0 1 (1.3%) 15 (19.0%) 4 (5.1%) 1 (1.3%) 1 (1.3%) 1 (1.3%)
Negative (−) 63 (100%) 62 (98.4%) 63 (100%) 74 (93.7%) 54 (68.4%) 69 (87.3%) 75 (95.0%) 77 (95.0%) 75 (95.0%)
Suspicious (?) 0 1 (1.6%) 0 4 (5.1%) 10 (12.7%) 6 (7.6%) 3 (3.8%) 1 (1.3%) 4 (5.1%)
Table 4 Subjective visual assessment pre- and post-IVGI and the subsequent change, or lack thereof, in the individual eyes evaluated
Pre-IVGI n = 86 eyes GOOD
42 (48.8%)
REDUCED
20 (23.3%)
POOR
24 (27.9%)
Post-IVGIn = 59 eyes GOOD
38 (64.4%)
REDUCED
8 (13.6%)
POOR
13 (22.0%)
Change in status following IVGI n = 59 eyes UNCHANGED
42 (71.2%)
IMPROVED*
11 (18.6%)
DETERIORATED**
6 (10.2%)
*from a POOR to a REDUCED or GOOD vision status or from a REDUCED to a GOOD vision status)**from a GOOD to REDUCED or POOR or from REDUCED to
POOR vision status due to cataract formation or phthisis bulbi
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Table 6 Combined serum and aqueous humor Leptospira titer results and the corresponding Leptospira c-value results
Titer negative
titer(s)
SINGLE SEROVAR
positive titer (< 1:400)
MULTIPLE SEROVARS
positive titers (1:100–1:400)
SINGLE SEROVAR
positive titer (> 1:400)
MULTIPLE SEROVARS
positive titers (> 1:400)
Serum
(n = 80)
41 (51.3%) 20 (25.0%) 10 (12.5%) 6 (7.5%) 3 (3.8%)
Aqueous humor
(n = 79)
49 (62.0%) 11 (13.9%) 1 (1.3%) 13 (16.5%) 5 (6.3%)
C-value
(different serovars)
NO positive
c-value
SINGLE positive
c-value (less than 4)
MULTIPLE positive
c-values (less than 4)
SINGLE positive
c-value (greater than 4)
MULTIPLE positive
c-values (greater than 4)
C-value
(n = 79)
50 (63.3%) 12 (15.2%) 1 (1.3%) 11 (13.9%) 5 (6.3%)
a b c
d
e
f
g
Fig. 2 Nine-year old warmblood gelding presented with chronic-acute, persistent panuveitis of the right eye (OD). Negative c-value for Leptospira. a. Initial
presentation: Blepharospasm, epiphora, diffuse corneal edema, 360° corneal neovascularization, + 4/4 flare, fibrin in anterior chamber and miosis were
present. The posterior aspect of the eye could not be visualized. Inflammation was controlled with medical therapy. b. One-hundred-fifteen
days post-initial presentation: Two additional bouts of inflammation since initial presentation. Both intravitreal gentamicin injection (IVGI) and
aqueocentesis were performed. Immature cataract and posterior synechia were present at the time of IVGI OD. c. Seven days post-IVGI OD: Immature
cataract. d. Sixty days post-IVGI OD: Medical treatment was discontinued 39 days prior to this examination. No signs of active inflammation could be
identified. e. One-hundred-thirteen days post IVGI OD: Mature cataract (cataract maturation). No signs of active inflammation. f. Three-hundred-twenty-seven
days post-IVGI OD: Uveitis remains controlled without medical treatment. g. Six-hundred-two days post-IVGI OD: No recurrent bouts of inflammation
since IVGI
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developed retinal degeneration and 1/5 (20%) of those,
where cataract progression was observed would have
not been included in our results, thus introducing a
false positive bias into our complication rates. One
cataract, that would not have been included other-
wise, developed when using preservative-free gentami-
cin. Thus, setting the minimum-follow-up period at a
time point further out from the IVGI (e.g., 5 months)
would have prevented inclusion of those complica-
tions from our results, as a result, an incorrect
conclusion would have been drawn that no cataract
progression/maturation occurred when utilizing PFG
for the IVGI. Future studies evaluating the clinical
outcome and the presence or development of
long-term complications over multiple years are ne-
cessary and are currently underway.
The present study reports control of ERU in 88.1%
(non-recurrence/non-persistence rate) in the absence of
medical treatment of the eyes with a minimum
follow-up period of 30 days. These results support the
a b1 b2
c d e
f
g
h
Fig. 3 Eight-year old warmblood mare that presented for chronic-acute, recurrent anterior uveitis in the left eye (OS). Negative c-value for
Leptospira. a. Initial presentation: Two days following the onset of an acute bout of inflammation. Topical and systemic therapy were initiated by
the referring veterinarian, when ocular signs were first identified. Inflammation was controlled via medical therapy. b1. Seven months after initial
presentation: Active uveitis OS; + 4/4 flare, fibrin and complete miosis were present. b2. Infrared picture of OS at the same examination as in B1.
c. Uveitis was controlled within 5 days of initiating medical therapy. d. Recurrent acute inflammation: 14 months later. Intravitreal gentamicin
injection (IVGI) and aqueocentesis were performed. e. Ninety-eight days post-IVGI OS: Uveitis has remained controlled following IVGI. A focal area
of tapetal hyperreflectivity identified during indirect ophthalmoscopy of the fundus. f. Fundus image of the lesion described in e. Retinal
degeneration developed between the 30- and 98- day recheck examination. Subjective vision status unchanged from pre-IVGI. g. Two-hundred-seventy
days post-IVGI OS: Uveitis controlled. Retinal degeneration remains static. h. Three-hundred-eighty-five days post-IVGI OS: Uveitis remains controlled. Retinal
degeneration remains static
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anecdotal findings reported by Pinard in 2005 with a
positive outcome of 94.4%, and those reported by
Kleinpeter in 2014 showing a positive outcome in 93.3%
(follow-up: 2–96month) [25, 29]. In the latter study, 11/
60 (18.3%) eyes became blind due to cataract formation
following IVGI [25]. When comparing this result to the
first 34 eyes in the present study that were treated with
gentamicin containing preservatives, similar rates of
cataract formation or maturation (4/34 (11.8%) eyes)
were observed [25]. Because cataract maturation was ob-
served most often in eyes with moderate pre-existing
cataracts, we speculated that the preservatives in Genta
100 may have contributed to the accelerated cataract
maturation in these cases. In order to minimize this risk,
we switched to PFG solution after making this ob-
servation. After switching to PFG, only a single cata-
ract progressed from immature to mature (1/52 eyes,
1.9%). Although the exact risk of cataract maturation
associated with PFG IVGI is unknown, it appears
that utilization of a PFG solution may help to
minimize the actual risk of developing this blinding
complication post-IVGI.
Conclusion
With less than 9% of the horses in the present study
developing recurrent or persistent inflammation, less
than 9% with cataract maturation and less than 6%
with retinal degeneration, IVGI was associated with a
lower level of complications compared with medical
therapy [3, 17, 18] and other commonly implemented
surgical treatment options for ERU (CSI placement
and PPV) [10–13]. The ability of low-dose IVGI with
4 mg gentamicin (especially PFG) to suppress active
inflammation in various types and stages of equine
uveitis in the present study despite the Leptospira sta-
tus of the eye, adds another treatment option in the
management of a severely debilitating and vision
threatening disease.
Methods
Case selection
Complete initial and all follow-up ophthalmic examina-
tions were performed by a board-certified veterinary
ophthalmologist (RJM) between January 2013 through
June 2016 in south-east Germany. Horses presenting
with signs of active or chronic uveitis and a history of
recurrences were included in the study. Signs associated
with recurrent or persistent uveitis included, but were
not limited to, blepharospasm, epiphora, keratic pre-
cipitates (KP), aqueous flare, fibrin in the anterior
chamber (AC), hyphema, miosis, corpora nigra atro-
phy or degeneration, iris hyper- or depigmentation,
equatorial vesicular cataracts, posterior lens capsule
adhesions or opacifications, vitreous body opacifica-
tions, and retinal detachment. Horses with uveitis
resulting from putative trauma, secondary to infec-
tious corneal diseases, or following intraocular sur-
gery, were excluded.
Owners were educated on the various medical and
surgical (i.e., PPV, CSI, and intravitreal injections) treat-
ment options, and risks associated with each option.
Client consent to perform the IVGI was obtained follow-
ing an in-depth discussion of potential complications
including failure of the selected treatment option to
control the disease, resulting in persistent/ recurrent in-
flammation with progression of ocular signs, and poten-
tial cataract maturation or development and retinal
degeneration or detachment.
Examination
Complete ophthalmic examinations were performed on
initial presentation, and on each subsequent follow-up
examination, and consisted of a subjective clinical vision
assessment (menace response) and neuro-ophthalmic
evaluation (dazzle, and pupillary light reflexes (PLR)),
slit lamp bio microscopy (Kowa SL-15),1 indirect oph-
thalmoscopy (Keeler Vantage),2 rebound tonometry
(TonoVet),3 external ocular fluorescein dye
Table 7 Individual variables with positive correlation to treatment outcome or the development of post-injection complications
Variable Treatment Outcome Post-Injection Complications
Breed Appaloosas: more recurrent inflammation than other breeds NC
Coat color Leopard patterned: more recurrent inflammation than other
coat colours
NC
Flare pre-IVGI NC NO flare: increased risk of retinal degeneration
Leptospira status of the eye Multiple positive C-values (≥4) for multiple individual
serovars: increased incidence of persistent inflammation
NC
Aqeuous humor titer in total Multiple positive individual aqueous humor titers for Leptospira
(≥1:400): increased incidence of persistent inflammation
NC
Single serum titer One positive serum titer for Leptospira (≥1:400): increased
incidence of persistent inflammation
NC
Abbreviations: NC no correlation
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application (Fluoreszein SE Thilo),4 and color (Nikon
D300s)5 and infrared (Nikon D200)5 (sensor conver-
sion)6 digital imaging. Aqueous flare was graded as
follows: 0 (none), 1 (faint), 2 (moderate), 3 (severe) or
4 (blood or fibrin present in the anterior chamber)
[30]. Fundus images (Kowa Genesis or ClearView)1,7
were obtained in horses with posterior segment abnor-
malities, when possible.
Categorization of uveitis
For statistical purposes, each case was diagnosed with
one of the following: 1. Panuveitis (global uveal inflam-
mation with equal distribution of clinical signs between
the anterior and posterior segment); (Figs. 2 and 4); 2.
Panuveitis with predominant anterior segment involve-
ment; 3. Panuveitis with predominant posterior segment
involvement; 4. Anterior uveitis; (Fig. 3); 5. Posterior
uveitis; and 6. Heterochromic iridocyclitis with second-
ary keratitis (HIK), a recently described, specific form of
idiopathic anterior uveitis (iridocyclitis) and corneal
endothelial inflammation associated with iris pigment
dispersion and retro-corneal fibrous membrane forma-
tion [2, 3, 8, 31].
Each case was further categorized as “acute” (active
inflammation without overt signs of chronicity),
“chronic” (signs of chronicity but no signs of active in-
flammation) or “acute/chronic” (acute onset of inflam-
mation associated with chronic inflammation).
“Recurrent uveitis” was diagnosed when at least 2 epi-
sodes of recurrent inflammation occurred despite appro-
priate medical therapy leading to a period of quiescence
following cessation of medical therapy. “Persistent in-
flammation” was diagnosed when an initial or recur-
rent bout of inflammation remained actively inflamed
for a minimum of four weeks despite aggressive and
appropriate medical or surgical therapy (Fig. 4).
The subjective vision status prior to, and following,
IVGI was graded as “good” (positive menace, dazzle,
direct and indirect PLR, with no evidence of obvious
visual field impairment due to corneal edema,
hyphema, hypopyon, fibrin in the anterior chamber,
miosis, synechia, lens opacities/cataracts, vitreal de-
generation, fundus abnormalities), “reduced” (positive
menace, dazzle, direct and indirect PLR with some
evidence of visual field impairment due to the abnor-
malities listed above) and “poor” (negative or positive
menace, dazzle and direct and indirect PLR with ob-
vious evidence of visual field impairment (late imma-
ture to mature cataracts), retinal degeneration/
detachment, or phthisis bulbi).
a b c
d e
Fig. 4 Twelve-year old warmblood mare that presented for a chronic-acute persistent panuveitis of the left eye (OS). Negative c-value for
Leptospira. a. Initial presentation: Diffuse corneal edema, keratic precipitates, + 2/4 flare, fibrin, vitreal degeneration and retinal folds were present.
Medical treatment was started (prednisolone acetate q 4–6 h, atropine q 8 h and flunixine meglumine 1.1 mg/kg twice daily). b. Ten days post
initial presentation: The clinical signs worsened in the face of aggressive medical treatment. Intravitreal gentamicin injection and aqueocentesis were
performed OS. c. Four days post-IVGI OS: Improvement of clinical signs can be readily appreciated. d. Twenty days post-IVGI OS: No flare present. e.
Forty-nine days post-IVGI OS: Uveitis remains controlled without medications. The mare was euthanized due to complications associated with cervical
spinal fracture 2months after IVGI
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Sedation, intravitreal gentamicin injection and aqueous
paracentesis
A general physical examination including auscultation
and body temperature measurement was performed
prior to sedation with a combination of detomidine
hydrochloride (Domosedan, 0.01–0.02 mg/kg bwt i.v.)8
and butorphanol (Alvegesic, 0.005–0.01 mg/kg bwt i.v.)9
intravenous and intramuscular bolus (0.02–0.04 mg/kg
bwt i.m.) injections. Blood (serum and EDTA) was
drawn and submitted for a complete blood count and
chemistry panel. A microscopic agglutination test
(MAT) for Leptospira antibodies was also routinely per-
formed [32]. A total of nine serovars (L. bratislava,10 L.
icterohaemorrhagiae/copenhageni10, L. australis10, L. po-
mona10, L. grippotyphosa10, L. autumnalis10, L.cani-
cola,11 L. saxkoebing11, L.sejroe11) were evaluated10,11 .
Following sedation, the horse’s head was positioned
atop a pair of pads placed on a mobile cart to increase
stability. Local akinesia and analgesia (palpebral and the
frontal nerve blocks) was achieved using 2% mepivacaine
(Scandicain 2%)12 [33]. Topical anesthetic ophthalmic
solution (proparacaine HCL 0.5%)13 was applied as
needed. The conjunctival fornices were irrigated with
1.0 ml of a dilute baby shampoo solution14 (1 ml of baby
shampoo in 1 l of balanced saline solution), 1.0 ml of a
1.0% dilute iodine solution,15 and 1.0 ml of balanced
saline solution (Acrisol)4 [34].
Dorsal globe exposure was facilitated with either a
Desmarres16 or prototype eyelid retractor,17 and further
enhanced by rotating the horse’s head away from the exam-
iner to exaggerate ventral globe rotation. The first 34 horses
were treated with a 4mg injectable gentamicin solution
containing preservatives (Genta100; 100mg/ml)9. All add-
itional horses (n = 52) were treated with preservative-free
gentamicin (PFG) (Gentamicin-ratiopharm, 160mg/2ml
SF).18 Undiluted gentamicin (0.04ml Genta100 or 0.05ml
PFG) 9,18 was drawn up in a 30- gauge needle/syringe
combination (12mm length, 1.0ml insulin syringe), and
the IVGI was performed using headloupes (magnification)
(Eschenbach MaxView with LED light source or
headloupes with a separate head-mounted light source
(ML4-LED))19,20,.21 The injection site was 10mm posterior
to the limbus at 12 o’clock. Injection was facilitated by
applying gentle but steady pressure while slowly and delib-
erately rotating the needle in a clockwise manner with the
needle directed toward the optic nerve head to avoid inad-
vertent contact with the lens. Aqueous paracentesis was
then performed using a second insulin syringe at either the
11:00 o’clock (right eye, oculus dexter, OD) or 1:00 o’clock
(left eye, oculus sinister, OS) positions. A total volume of 1
ml aqueous humor was aspirated. Aqueous humor and
serum samples were refrigerated prior to transport to the
laboratory. MAT tests for Leptospira titers were per-
formed with the serum and aqueous humor, and
real-time PCR was used for the detection of Leptos-
pira DNA in the aqueous humor [35]. With the help
of the C-value (dividing the aqueous humor Leptos-
pira antibody titer by the serum Leptospira antibody
titer), eyes were categorized into Leptospira “positive”
(C-value greater than 3), “Leptospira suspicious”
(C-value between 1 and 3) and “Leptospira negative”
(C-value of 0) for statistical evaluation [27, 36].
Post-injection therapy
Post IVGI medical therapy consisted of topical antibi-
otics (Ofloxacin)22 q8h for one week, and topical corti-
costeroids (Prednisolone acetate)23 or nonsteroidal
anti-inflammatory drugs (NSAIDs) (Bromfenac)22 that
were gradually tapered over the course of 4–8 weeks based
on each horse’s individual response to therapy. Either 1%
tropicamide24 or 1% atropine25 were applied topically for
a variable duration to maintain or achieve mydriasis and
to stabilize the blood aqueous barrier. Systemic NSAIDs
(flunixin-meglumine, 0.55mg/kg, p.o., q12h)9 were also
administered per os and gradually tapered-off over the
course of 7 to 14 days. A prophylactic dose of 37% omep-
razole (Gastrogard, 2mg/kg p.o.)26 was routinely adminis-
tered orally, once daily while using systemic NSAIDs.
Follow-up examination
Following IVGI all eyes were immediately examined for the
presence of peri-injection complications (subconjunctival
or intracameral hemorrhage), and re-examined within 24 h.
Horses were monitored weekly for the first month or until
medications were discontinued. Subsequent follow-up ex-
aminations were spaced further apart based on the horse’s
individual response to treatment. Inflammation was consid-
ered controlled if no signs of recurrent or persistent uveitis,
independent of complications, were identified at any
follow-up examination after medications had been discon-
tinued. Particular attention was paid at all times to the pos-
sible development of post-injection complications (cataract
formation/maturation, retinal degeneration).
Data analysis
All 86 eyes were evaluated for peri-injection complica-
tions (subconjunctival and intracameral hemorrhage),
but only those with a minimum follow-up period of 30
days (59 eyes) were included in the post-injection statis-
tical data evaluation. These latter eyes were monitored
for signs of recurrent or persistent inflammation, as well
as for the presence of additional complications or seque-
lae (e.g., cataract formation/progression and retinal
degeneration). Correlation between the outcome
(controlled, recurrent, or persistent inflammation),
post-injection complications (no complications, cata-
ract formation or maturation, and retinal degener-
ation), and possible influencing factors (breed, coat
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color, gender, clinical diagnosis with chronic or acute
and recurrent or persistent, Leptospira status of the
eye, Leptospira PCR, individual C-values for each
Leptospira serovar, the combined C-value, the
Leptospira serum and aqueous humor titer, response
to topical medication prior to IVGI, severity of signs, fre-
quencies of recurrence, gentamicin with preservatives,
PFG, visual reflex tests, vision status prior to IVGI, miosis
before IVGI, subconjunctival hemorrhage, intracameral
hemorrhage and glaucoma prior to IVGI) were deter-
mined using a Pearson’s chi-squared test or a Fisher’s
exact test. To avoid same-animal correlation, a single eye
per horse was randomly selected for inclusion in the study
from those receiving bilateral IVGI. Differences with
P ≤ 0.05 were considered significant. Results were
calculated using computerized statistical software
(IBM SPSS 23.0).27
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